Pharmaceuticals distributor Cardinal Health (NYSE:CAH) reported increased, adjusted first-quarter earnings, but investors showed only modest enthusiasm as the company’s full-year outlook remained the same. Cardinal reported adjusted earnings from continuing operations of $256 million, or 73 cents per diluted share, compared with $231 million or 66 cents per diluted share a year earlier, according to […]
Cardinal Health (NYSE:CAH) has acquired for $165 million a Canadian medical products supplier that focuses on selling to nursing homes. The purchase of Futuremed Healthcare Products strengthens Dublin, Ohio-based Cardinal’s presence in Canada and offers Cardinal new customers for its existing medical products. Futuremed specializes in selling consumable nursing home supplies and furniture, and equipment […]
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Cardinal Health (NYSE:CAH) has secured exclusive North American marketing rights for a recently cleared staph-infection blood test from diagnostics company MicroPhage. In exchange, Dublin, Ohio-based Cardinal has provided MicroPhage with an unspecified amount of operational funding for development and commercialization of new products, according to a statement from MicroPhage. Reached by phone, MicroPhage officials declined […]
While just a small part of Cardinal Health‘s (NYSE:CAH) $100 billion-plus revenue, the nuclear medicine business is an important driver of higher margins for the drug distribution company. In particular, positron emission tomography (PET) radiopharmaceuticals — which are used to aid in imaging scans for cancer, heart disease and brain disorders — are poised to […]
Cardinal Health (NYSE:CAH) sees a big growth opportunity in the specialty drugs distribution market, but catching up with its top two rivals could be a tough slog. Specialty drugs are typically complex, injectable biologics that are used to treat somewhat small groups of patients for specific conditions like multiple sclerosis, cystic fibrosis and certain types […]
Drug distributor Cardinal Health (NYSE: CAH) reported a 19 percent fourth-quarter increase in sales of generic drugs, an area that continues to be a strength for the company. Generics — as well as acquisitions that have allowed the company to sell more generics — contributed to a 9 percent increase in fourth-quarter revenue to $26.8 […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) has opened a molecular imaging center with the goal of developing new radioactive imaging agents that will help doctors treat a wide range of diseases like cancer, heart disease and neurological disorders. Cardinal scientists, engineers and manufacturing experts will work with clients in the pharmaceutical and academic research industries […]
Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health (NYSE:CAH) has had an apparent change of opinion. The giant drug distributor – and Ohio’s largest company – does not plan to lease space in the planned Cleveland medical mart or its counterpart in Nashville, spokeswoman Corey Kerr said. So don’t […]
The capital punishment-opposing nun prominently featured in the movie “Dead Man Walking” has asked Cardinal Health (NYSE: CAH) to recall a drug that’s used in the execution of prisoners. But Sister Helen Prejean isn’t likely to be pleased with the response from the Dublin, Ohio-based pharmaceuticals distributor. A Cardinal spokeswoman was asked multiple times whether […]
Medical products supplier Cardinal Health (NYSE:CAH) raised its full-year earnings expectations, driven in part by a 25 percent increase in third-quarter profits in its pharmaceutical business. Dublin, Ohio-based Cardinal now expects adjusted full-year earnings per share from continuing operations between $2.61 and $2.67, according to a statement from the company. CEO George Barrett cited strong […]
After a little more than a year on the job, a Cardinal Health (NYSE:CAH) board member is stepping down for health reasons. Dr. James Mongan’s resignation comes “due to health-related reasons,” and “is not the result of any disagreement with [Cardinal] on any matter relating to the [its] operations, policies or practices,” according to a […]
Cardinal Health (NYSE:CAH) and pharmaceuticals distributors of its ilk will have few better friends over the coming years than generic drugs. The so-called “generic wave” — created by scores of brand-name drugs whose patents are expiring between this year and 2015 — is expected to be a huge boon to drug wholesalers like Dublin, Ohio-based […]
Drug distributor Cardinal Health (NYSE:CAH) raised its earnings outlook for 2011 after it reported an 11 percent increase in the profits of its pharmaceuticals business unit in its fiscal second quarter.
As generic drugs increasingly replace brand names in the coming years, pharmaceuticals wholesalers like Cardinal Health (NYSE:CAH) will see their operating profits rise "dramatically," according to a report from Barclays Capital.
Cardinal Health (NYSE: CAH), Ohio's largest company by revenues, led the state's health organizations in federal lobbying spending last year at nearly $1.3 million. Cardinal, a pharmaceuticals distributor and medical products supplier, upped its federal lobbying spending by 39 percent over the prior year, publicly filed lobbying reports revealed.